According to a poster presented at the 2021 American Society of Clinical Oncology Genitourinary Cancers Symposium, a higher starting dose of lenvatinib (Lenvima) improved health-related quality of life and led to longer time to deterioration compared with a lower starting dose of lenvatinib in patients with renal cell carcinoma (RCC).
“Based on these findings, patients who received lenvatinib 18 mg starting dose had better quality of life and less severe symptoms than those who received lenvatinib 14 mg starting dose,” said Cristiane Decat Bergerot, PhD, MS, BS, a postdoctoral fellow at City of Hope National Medical Center in Duarte, California, during the virtual poster presentation. “In addition, participants who received lenvatinib 18 mg maintained quality of life and symptom control for longer than those who received lenvatinib 14 mg starting dose.”
In this phase 2,…
